Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 3/2011

01-06-2011

Ablative Therapies for Barrett’s Esophagus

Authors: Katherine S. Garman, Nicholas J. Shaheen

Published in: Current Gastroenterology Reports | Issue 3/2011

Login to get access

Abstract

Barrett’s esophagus has gained increased clinical attention because of its association with esophageal adenocarcinoma, a cancer with increasing incidence and poor survival rates. The goals of ablating Barrett’s esophagus are to decrease esophageal cancer rates and to improve overall survival and quality of life. Different techniques have been developed and tested for their effectiveness eradicating Barrett’s epithelium. This review assesses the literature associated with different ablative techniques. The safety and efficacy of different techniques are discussed. This review concludes with recommendations for the clinician, including specific strategies for patient care decisions for patients with Barrett’s esophagus with varying degrees of dysplasia.
Literature
1.
Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003;98:1627–33.PubMed
2.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
3.
Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98–100.PubMedCrossRef
4.
Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–7.PubMedCrossRef
5.
Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–7.PubMedCrossRef
6.
Hayeck TJ, Kong CY, Spechler SJ, et al. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23:451–7.PubMedCrossRef
7.
Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333–8.PubMedCrossRef
8.
Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–44. quiz e32.PubMedCrossRef
9.
• Shaheen NJ, Sharma P, Overholt BF, et al.: Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277–88. This randomized clinical trial evaluated radiofrequency ablation in patients with dysplastic BE. PubMedCrossRef
10.
Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–98.PubMedCrossRef
11.
Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008;6:159–64.PubMedCrossRef
12.
Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol. 2009;7:613–23.PubMedCrossRef
13.
• Shaheen NJ, Peery AF, Hawes RH, et al.: Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. Endoscopy 2010;42:790–9. This article is one of the few reports of quality of life in patients with BE who undergo ablation. PubMedCrossRef
14.
Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007;132:1226–33.PubMedCrossRef
15.
Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology. 2009;136:2101–14. e1-6.PubMedCrossRef
16.
Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.PubMedCrossRef
17.
Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–78.PubMedCrossRef
18.
Ajumobi A, Bahjri K, Jackson C, Griffin R. Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci. 2010;55:1615–21.PubMedCrossRef
19.
Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788–97.PubMedCrossRef
20.
Lichtenstein DR, Cash BD, Davila R, et al. Role of endoscopy in the management of GERD. Gastrointest Endosc. 2007;66:219–24.PubMedCrossRef
21.
Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci. 2010;55:1918–31.PubMedCrossRef
22.
Falk GW. Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves. Dig Dis Sci. 2010;55:1811–4.PubMedCrossRef
23.
Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC: Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010:CD004060.
24.
Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996;44:532–5.PubMedCrossRef
25.
Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc. 2001;53:554–8.PubMedCrossRef
26.
Sharma P, Bhattacharyya A, Garewal HS, Sampliner RE. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest Endosc. 1999;50:159–64.PubMedCrossRef
27.
Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc. 2005;61:232–40.PubMedCrossRef
28.
Sharma P, Wani S, Weston AP, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut. 2006;55:1233–9.PubMedCrossRef
29.
Bright T, Watson DI, Tam W, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results. Ann Surg. 2007;246:1016–20.PubMedCrossRef
30.
Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.PubMedCrossRef
31.
Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma–an American single-center experience. Am J Gastroenterol. 2009;104:2684–92.PubMedCrossRef
32.
Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut. 2000;47:612–7.PubMedCrossRef
33.
Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460–8.PubMedCrossRef
34.
Badreddine RJ, Prasad GA, Wang KK, et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc. 2010;71:697–703.PubMedCrossRef
35.
Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004;53:785–90.PubMedCrossRef
36.
Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004;20:1289–96.PubMedCrossRef
37.
Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–95.PubMedCrossRef
38.
Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–76.PubMedCrossRef
39.
• Fleischer DE, Overholt BF, Sharma VK, et al.: Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010;42:781–9. This study presents some of the longest follow-up data regarding ablation of nondysplastic BE as presented in the AIM-II study. PubMedCrossRef
40.
Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus. 2007;20:516–22.PubMedCrossRef
41.
Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy. 2008;40:359–69.PubMedCrossRef
42.
Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370–9.PubMedCrossRef
43.
Sharma VK, Kim HJ, Das A, et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy. 2008;40:380–7.PubMedCrossRef
44.
Hernandez JC, Reicher S, Chung D, et al. Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy. 2008;40:388–92.PubMedCrossRef
45.
Sharma VK. Jae Kim H, Das A, et al.: Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol. 2009;104:310–7.PubMedCrossRef
46.
Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc. 2008;68:35–40.PubMedCrossRef
47.
Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8:23–9.PubMedCrossRef
48.
Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned. Surg Endosc. 2009;23:2175–80.PubMedCrossRef
49.
Vassiliou MC, von Renteln D, Wiener DC, et al. Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation. Surg Endosc. 2010;24:786–91.PubMedCrossRef
50.
Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–8.PubMedCrossRef
51.
Dumot JA, Vargo 2nd JJ, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009;70:635–44.PubMedCrossRef
52.
Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc. 2005;62:16–23.PubMedCrossRef
53.
Chennat J, Konda VJ, Hart J, et al.: Complete Barrett's eradication endoscopic mucosal resection (CBE-EMR): long-term results of management of high grade dysplasia (HGD) and intramucosal carcinoma (IMC). In: Digestive Disease Week; 2010 May 2010; 2010. p. S1517.
54.
• Pouw RE, Seewald S, Gondrie JJ, et al.: Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010;59:1169–77. This is one of the largest studies of endoscopic mucosal resection as a strategy for ablation of BE. PubMedCrossRef
55.
Van Vilsteren FG, Pouw RE, Seewald S, et al. A multi-center randomized trial comparing stepwise radical endoscopic resection versus radiofrequency ablation for Barrett esophagus containing high-grade dysplasia and/or early cancer, Abstract 939. Gastrointest Endosc. 2009;69:AB133–4.CrossRef
56.
Eldaif SM, Lin E, Singh KA, et al. Radiofrequency ablation of Barrett's esophagus: short-term results. Ann Thorac Surg. 2009;87:405–10. discussion 10–1.PubMedCrossRef
57.
• Shaheen NJ, Greenwald BD, Peery AF, et al.: Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010;71:680–5. This study represents one of the largest reports of cryotherapy for ablation of BE. PubMedCrossRef
Metadata
Title
Ablative Therapies for Barrett’s Esophagus
Authors
Katherine S. Garman
Nicholas J. Shaheen
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 3/2011
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-011-0182-z

Other articles of this Issue 3/2011

Current Gastroenterology Reports 3/2011 Go to the issue

ReviewPaper

Evaluation of Patients with Suspected Laryngopharyngeal Reflux: A Practical Approach

ReviewPaper

Diagnosis of Eosinophilic Esophagitis: Current Approach and Future Directions

ReviewPaper

Obesity and GERD: Pathophysiology and Effect of Bariatric Surgery

ReviewPaper

Current Approach to the Treatment of Achalasia

ReviewPaper

Exploring the Differential Diagnosis of Joint Complaints in Pediatric Patients with Inflammatory Bowel Disease

ReviewPaper

GERD-Related Cough: Pathophysiology and Diagnostic Approach
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits